Telomir Pharmaceuticals, Inc.
TELO
$4.55
-$0.48-9.54%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -50.98% | 511.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -51.63% | 307.34% | |||
| Operating Income | 51.63% | -307.34% | |||
| Income Before Tax | 51.62% | -313.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.62% | -313.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.62% | -313.44% | |||
| EBIT | 51.63% | -307.34% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 51.71% | -313.70% | |||
| Normalized Basic EPS | 51.70% | -313.40% | |||
| EPS Diluted | 51.71% | -313.70% | |||
| Normalized Diluted EPS | 51.70% | -313.40% | |||
| Average Basic Shares Outstanding | 0.17% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
